Jasdave Chahal

Jasdave Chahal is the founder and chief scientist of Tiba Biotech, a company that develops RNA nanoparticle vaccines. Jasdave has a background in research and has worked as a research scientist at the Massachusetts Institute of Technology, where they developed RNA nanoparticle vaccines against viral pathogens. Jasdave has also worked as a course instructor at MIT, co-teaching a course on the molecular and immunological mechanisms underlying the causes of infectious diseases. Chahal did their postdoctoral work at the Whitehead Institute, where they developed synthetic self-replicating RNA vaccines using engineered alphaviral genomes. Jasdave has evaluated vaccines using in vivo immunoassays in mouse models of Toxoplasma gondii, influenza, and Ebola virus infection and cervical cancer, melanoma, and pancreatic cancer models.

Jasdave Chahal received a Doctor of Philosophy in Molecular Biology from Princeton University in 2012. Prior to that, they completed a Bachelor of Science in Biopharmaceutical Science from the University of Ottawa in 2006. During their time at the University of Ottawa, they conducted research under Dr. J.T. Arnason in molecular and plant biology, and also managed the chemical and equipment inventory for the Faculty of Science’s Environmental Health and Safety department. They graduated summa cum laude and received the Dr. Goodman Cohen Summer Student Research Award from the Ontario Health Research Institute in 2005.